Inovise Medical, a privately held cardiac diagnostic company, has raised $12.5 million in new capital to support development of technology that combines electrical and sound information to evaluate cardiac conditions associated
Inovise Medical, a privately held cardiac diagnostic company, has raised $12.5 million in new capital to support development of technology that combines electrical and sound information to evaluate cardiac conditions associated with coronary artery disease, left ventricular hypertrophy, acute coronary syndrome, and heart failure. This latest round of financing, which was led by new investors MDS Capital and TAT Capital Partners, brings the total equity investment in the firm to $22 million. The company could release its first product later this year. Managers from Hewlett-Packard founded Inovise Medical in 1997.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.